Skip to content

IRON: 12 Funds Holding, Catalyst in 17d | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Free TrialStart 14-Day Free Trial

Home›Companies›Disc Medicine Inc. (IRON)

Disc Medicine Inc.

IRON

Held by 12 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

12 funds opened new positions. Next phase3 readout (Placebo): Sep 2026. Short interest: 22.1% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: John D. QuiselIPO: 2020Website ↗

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

8.0/10

12 funds opened new positions●●

Recent insider sells only●●

Phase2 readout in 17 days●●

Held by 12 specialist funds●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

12 specialist funds hold IRON with a Phase 2 in 17 days for DISC-0974 (Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia)

+3 more upcoming catalysts

OrbiMed Advisors Casdin Capital BVF Partners Baker Bros. Advisors RTW Investments Perceptive Advisors Eventide Asset Management Deerfield Management Rock Springs Capital Cormorant Asset Management RA Capital Management Boxer Capital

Fund Holdings

12 fund convergence

OrbiMed AdvisorsHeld 7Q ↓

Casdin CapitalHeld 2Q

BVF PartnersHeld 3Q ↑

Baker Bros. AdvisorsHeld 7Q ↑

RTW InvestmentsHeld 3Q

Perceptive Advisors

Eventide Asset ManagementHeld 6Q ↑

Deerfield ManagementHeld 7Q

Rock Springs Capital

Cormorant Asset Management

RA Capital ManagementHeld 6Q ↑

Position history (shares)

OrbiMed Advisors

7Q Casdin Capital

2Q BVF Partners

3Q Baker Bros. Advisors

7Q RTW Investments

3Q Perceptive Advisors

2Q Eventide Asset Management

AI Signal

Perceptive Advisors fully exited IRON ahead of a crowded catalyst runway, a notable divergence from 11 remaining specialist holders including Baker Bros., RA Capital, and Cormorant. The exit comes with DISC-1459's Phase 3 EPP readout not until mid-2028 and the more near-term Phase 2 DISC-0974 data in myelofibrosis/anemia not until May 2027, suggesting Perceptive may have concluded the risk/reward across this timeline no longer justifies the position. With ~6.7 quarters of runway, dilution risk is manageable but not immaterial heading into multiple capital-intensive trials, and the persistence of high-conviction specialist ownership makes this a split-camp situation worth monitoring closely.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Feb 17, 2026

$398.8M

7 funds

May 15, 2026

$402.0M

8 funds

May 29, 2026

$0

0 funds

Aug 14, 2026

$399.2M

8 funds

+226745% total institutional value over 22 quarters

Cash Runway

Total Liquidity

Unverified

Quarterly Burn

Unverified

Runway

6.7 quarters

As of

Jun 30, 2026

Short Interest

High short interestSI rising 7 periods (+39.1%)

Short Shares

7.27M

Change

-1.3%

Days to Cover

12.7

% of Float

22.1%

Settlement

Sep 30, 2026

Short interest over 12 periods

Catalysts

Phase 2Q1 2024DISC-1459Erythropoietic ProtoporphyriaNCT05308472

Phase 3Q3 2026PlaceboErythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)NCT06910358

Primary: Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment (24 weeks)Enrollment:183/183Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026DISC-0974Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); AnemiaNCT07368972

Primary: Maximal change from baseline in Hgb through Day 85 (up to 85 days)Enrollment:Target 21Sites: 15RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2027DISC-3405Polycythemia Vera (PV)NCT06985147

Primary: Number of participants with treatment-related adverse events as assessed by CTCAE (Up to 365 days)Enrollment:Target 60Sites: 15NA, TREATMENT

Phase 2Q2 2027DISC-0974Myelofibrosis; Anemia, Anemia, MyelofibrosisNCT05320198

Phase 3Q2 2028DISC-1459Erythropoietic ProtoporphyriaNCT05883748

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GRA Capital Management5.9%Jan 7, 2026

SC 13D/AOrbiMed Advisors4.5%Mar 12, 2025

Recent Insider Activity

Bitterman KevinDirector

SaleSep 15, 2026

Start free trial for dollar amounts, share counts, and AI context.

Position Details

OrbiMed AdvisorsTRIMMEDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

102 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

1 insider transaction with share counts, dollar amounts, price per share, and AI context — locked.

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ETNB4 funds GPCR4 funds INSM4 funds FDMT3 funds AXSM3 funds CTMX3 funds IDYA3 funds IMVT3 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

What Academic Research Says About Form 4 Insider Trading in Biotech Small Caps

8 min read

Biotech Penny Stocks with Insider Buying: What the Data Shows

7 min read

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Deerfield Management

7Q

RA Capital Management